When we noticed the massive enrichment of CDX2 loss within MSI-H tumours, we decided to look into the prognostic relevance of all parameters within microsatellite subgroups of the overall cohort and Stage II/III cancers and observed that CDX2 has a considerable prognostic impact in MSS tumours, but shows no prognostic relevance in MSI-H CRCs, where tumour budding and the different CRC subtypes (but not WHO grade) showed a high prognostic significance. The gene discussed is CDX2; the disease is neoplasm.